acalabrutinib
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: Tyrosine-protein kinase BTK.
- Target
- Tyrosine-protein kinase BTK
- Mechanism
- Tyrosine-protein kinase BTK inhibitor
pharma · Chronic Lymphocytic Leukemia · Relapsing Multiple Sclerosis · TGTX
TG THERAPEUTICS
TG THERAPEUTICS, INC.
TG THERAPEUTICS drug portfolio — 23 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
3020 Carrington Mill Blvd, Suite 475, Morrisville, North Carolina 27560, US HQ
2011 Founded
521 Employees
Public company Type
TGTX · NYSE Ticker
Company details
- Status
- Public
- HQ
- 3020 Carrington Mill Blvd, Suite 475, Morrisville, North Carolina 27560, US
- Founded
- 2011
- Employees
- 521
- Programs
- 39
- Drugs
- 23
- Patents
- 7
TG THERAPEUTICS pipeline
Portfolio lens on 23 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.
TG THERAPEUTICS drug portfolio — 23 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Drug portfolio
-
-
Development asset linked to TG THERAPEUTICS in public FDA and regional records.
-
brentuximab vedotin
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: Tubulin.
- Target
- Tubulin
- Mechanism
- Tubulin inhibitor
-
US regulatory status: approved. Mechanism: Unknown.
- Mechanism
- Unknown
-
Development asset linked to TG THERAPEUTICS in public FDA and regional records. Mechanism: Histamine H1 receptor antagonist.
- Mechanism
- Histamine H1 receptor antagonist
-
US regulatory status: approved. Molecular target: DNA.
- Target
- DNA
- Mechanism
- DNA inhibitor
-
US regulatory status: approved. Molecular target: Programmed cell death 1 ligand 1.
- Target
- Programmed cell death 1 ligand 1
- Mechanism
- Programmed cell death 1 ligand 1 inhibitor
-
US regulatory status: approved. Molecular target: Glucocorticoid receptor.
- Target
- Glucocorticoid receptor
- Mechanism
- Glucocorticoid receptor agonist
-
Development asset linked to TG THERAPEUTICS in public FDA and regional records. Mechanism: Histamine H1 receptor antagonist.
- Mechanism
- Histamine H1 receptor antagonist
-
US regulatory status: approved. Molecular target: Histamine H1 receptor.
- Target
- Histamine H1 receptor
- Mechanism
- Histamine H1 receptor antagonist
-
fingolimod
Antineoplastic and immunomodulating agents (L04)US regulatory status: approved. Mechanism: Sphingosine 1-phosphate receptor binding agent.
- Mechanism
- Sphingosine 1-phosphate receptor binding agent
-
US regulatory status: approved. Mechanism: Diagnostic agent.
- Mechanism
- Diagnostic agent
-
Development asset linked to TG THERAPEUTICS in public FDA and regional records.
-
US regulatory status: approved. Molecular target: Glucocorticoid receptor.
- Target
- Glucocorticoid receptor
- Mechanism
- Glucocorticoid receptor agonist
-
obinutuzumab
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: B-lymphocyte antigen CD20.
- Target
- B-lymphocyte antigen CD20
- Mechanism
- B-lymphocyte antigen CD20 binding agent
-
Development asset linked to TG THERAPEUTICS in public FDA and regional records. Molecular target: Fatty-acid amide hydrolase 1.
- Target
- Fatty-acid amide hydrolase 1
- Mechanism
- Anandamide amidohydrolase inhibitor
-
pembrolizumab
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: Programmed cell death protein 1.
- Target
- Programmed cell death protein 1
- Mechanism
- Programmed cell death protein 1 inhibitor
-
Development asset linked to TG THERAPEUTICS in public FDA and regional records.
-
US regulatory status: approved. Molecular target: Glucocorticoid receptor.
- Target
- Glucocorticoid receptor
- Mechanism
- Glucocorticoid receptor agonist
-
ublituximab
Antineoplastic and immunomodulating agents (L04)Antineoplastic and immunomodulating agents (L04) compound in TG THERAPEUTICS's portfolio. Molecular target: B-lymphocyte antigen CD20.
- Target
- B-lymphocyte antigen CD20
- Mechanism
- B-lymphocyte antigen CD20 binding agent
-
US regulatory status: approved. Molecular target: B-lymphocyte antigen CD20.
- Target
- B-lymphocyte antigen CD20
- Mechanism
- B-lymphocyte antigen CD20 binding agent
-
US regulatory status: approved. Molecular target: Casein kinase I isoform epsilon.
- Target
- Casein kinase I isoform epsilon
- Mechanism
- Tyrosine-protein kinase ABL inhibitor
-
venetoclax
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: Apoptosis regulator Bcl-2.
- Target
- Apoptosis regulator Bcl-2
- Mechanism
- Apoptosis regulator Bcl-2 inhibitor